aTyr Pharma
ATYR
39 hedge funds and large institutions have $87.6M invested in aTyr Pharma in 2017 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 3 closing their positions.
4,360% more capital inflows, than outflows
Capital inflows: $21.1M | Capital outflows: $473K
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
26.06% more ownership
Funds ownership: 46.7% → 72.76% (+26%)
22% more funds holding
Funds holding: 32 → 39 (+7)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Redmile Group
San Francisco,
California
|
+$6.24M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$5.88M |
| 3 |
EcoR1 Capital
San Francisco,
California
|
+$5.43M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.24M |
| 5 |
AG
Artal Group
Luxembourg
|
+$827K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$280K |
| 2 |
Goldman Sachs
New York
|
-$75K |
| 3 |
BlackRock
New York
|
-$68.7K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$21K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$18.3K |
ATYR Hedge Fund Activity: Q3 2017 in Review
39 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q3 2017, worth a combined $87.6M — up 130% from $38M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ATYR positions and 3 closed out — a net gain of 8 holders — while 5 added to existing stakes and 8 trimmed.
The largest buyer was Redmile Group, opening a new position worth an estimated $6.24M. The largest seller was Alyeska Investment Group, cutting an estimated $280K.
- 39 institutional investors held aTyr Pharma (ATYR) as of Q3 2017, up from 32 in Q2 2017.
- Funds reported $87.6M of aTyr Pharma stock for Q3 2017, up 130% quarter-over-quarter.
- 11 funds opened new aTyr Pharma positions in Q3 2017 and 3 closed out, a net change of +8 holders.
- The largest aTyr Pharma buyer in Q3 2017 was Redmile Group, an estimated $6.24M added.
- The largest aTyr Pharma seller in Q3 2017 was Alyeska Investment Group, an estimated $280K sold.
Based on aggregated 13F filings for Q3 2017.